Skip to main content

Advertisement

SpringerLink
Log in

For choosing axillary treatment, and adjuvant hormonal treatment

  • Editorial
  • Published:
Breast Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26:1533–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, et al. Personalization of loco-regional care for primary breast cancer patients (part 1). Future Oncol. 2015;11:1297–300. doi:10.2217/fon.15.65.

    Article  CAS  PubMed  Google Scholar 

  3. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107–18. doi:10.1056/NEJMoa1404037.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Hayes DF. Clinical utility of genetic signatures in selecting adjuvant treatment: risk stratification for early vs. late recurrences. Breast. 2015. doi:10.1016/j.breast.2015.07.002.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Cancer Unit, Kyoto University Hospital, Breast Surgery, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto, 606-8507, Japan

    Masakazu Toi

  2. Breast Oncology Center, Cancer Institute Hospital, Tokyo, Japan

    Shinji Ohno

  3. International Medical Center, Breast Oncology, Saitama Medical University, Saitama, Japan

    Toshiaki Saeki

  4. Division of Breast Surgical Oncology, Department of Surgery, Showa University, Tokyo, Japan

    Seigo Nakamura

  5. Breast Center, Kantonsspital St. Gallen, St. Gallen, Switzerland

    Beat Thürlimann

Authors
  1. Masakazu Toi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinji Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshiaki Saeki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seigo Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Beat Thürlimann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masakazu Toi.

Ethics declarations

Conflict of interest

Masakazu Toi, Shinji Ohno, Seigo Nakamura, and Beat Thürlimann have no COI; Toshiaki Saeki received lecture fees from Novartis and Taiho Pharmaceutical Co. Ltd.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 78 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toi, M., Ohno, S., Saeki, T. et al. For choosing axillary treatment, and adjuvant hormonal treatment. Breast Cancer 23, 167–169 (2016). https://doi.org/10.1007/s12282-015-0662-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-015-0662-3

Keywords

Search

Navigation